TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET

Rhea-AI Summary

TYME Technologies, Inc. (NASDAQ: TYME) will report its second quarter fiscal 2022 financial results on November 8, 2021, at 8:30 AM ET. The call will be hosted by CEO Richie Cunningham and CFO Frank Porfido. A webcast of the event will be accessible on the company’s Investors page and archived for 90 days. Additionally, a Q&A session will follow the presentation, with questions accepted until 5:00 PM ET on November 4, 2021. TYME focuses on developing cancer metabolism-based therapies, particularly its compound SM-88.

• Company to report its second quarter fiscal 2022 financial results

BEDMINSTER, N.J.--(BUSINESS WIRE)-- TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its second quarter 2022 financial results on Monday, November 8, 2021 at 8:30 AM ET.

Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows:

Date:	Monday, November 8, 2021
Time:	8:30 AM ET
Toll-free (U.S.)	(866) 601-3896
International	(636) 812-6499
Conference ID	5953454

The webcast will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com, and will be archived for 90 days following the event.

Following the Company’s presentation, there will be a Q&A session. Management will address both live questions and those submitted in advance via email to lwilson@insitecony.com. The deadline to submit questions for the conference call is 5:00 PM ET on November 4, 2021.

About TYME Technologies, Inc.

TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company is currently focused on developing its novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas and breast, reinforce the potential of our emerging CMBT™ pipeline.

For more information, visit www.tymeinc.com. Follow us on social media: Facebook, LinkedIn, Twitter, YouTube and Instagram.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME's control. Factors that could cause actual results to differ materially from these forward-looking statements include the Company’s ability to successfully implement its clinical and other plans, competitive and regulatory developments, and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form

10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on June 10, 2021, as well as subsequent reports and filings from time to time with the SEC.

The information contained in this press release is as of release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005875/en/

INVESTORS AND MEDIA:

In-Site Communications

Lisa M. Wilson

T: 212-452-2793

E: lwilson@insitecony.com

Source: TYME Technologies, Inc.

FAQ

When will TYME report its second quarter 2022 financial results?

TYME will report its second quarter 2022 financial results on November 8, 2021, at 8:30 AM ET.

Who will host the TYME financial results conference call?

The conference call will be hosted by CEO Richie Cunningham and CFO Frank Porfido.

How can I access the TYME financial results webcast?

The webcast will be available on the Investors page of the TYME website and archived for 90 days.

What time is the TYME financial results conference call?

The TYME financial results conference call is scheduled for 8:30 AM ET on November 8, 2021.

What is the deadline for submitting questions for the TYME conference call?

Questions for the TYME conference call can be submitted until 5:00 PM ET on November 4, 2021.

What is the focus of TYME Technologies, Inc.?

TYME is focused on developing cancer metabolism-based therapies, particularly the compound SM-88.